Chris Schott
Stock Analyst at JP Morgan
(3.54)
# 783
Out of 4,829 analysts
127
Total ratings
56.63%
Success rate
1.8%
Average return
Main Sectors:
Stocks Rated by Chris Schott
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BIIB Biogen | Maintains: Neutral | $185 → $175 | $118.17 | +48.09% | 4 | May 5, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Overweight | $1,100 → $1,000 | $527.78 | +89.47% | 6 | Mar 31, 2025 | |
| GILD Gilead Sciences | Maintains: Overweight | $120 → $130 | $96.91 | +34.15% | 5 | Mar 27, 2025 | |
| AMRX Amneal Pharmaceuticals | Upgrades: Overweight | $9 → $12 | $7.41 | +61.94% | 2 | Feb 24, 2025 | |
| ABBV AbbVie | Maintains: Overweight | $210 → $200 | $184.60 | +8.34% | 2 | Nov 13, 2024 | |
| TEVA Teva Pharmaceutical Industries | Maintains: Neutral | $16 → $18 | $16.93 | +6.32% | 15 | Oct 21, 2024 | |
| IDXX IDEXX Laboratories | Maintains: Overweight | $630 → $575 | $491.70 | +16.94% | 7 | Oct 11, 2024 | |
| ZTS Zoetis | Maintains: Overweight | $225 → $230 | $159.27 | +44.41% | 2 | Oct 11, 2024 | |
| LLY Eli Lilly and Company | Maintains: Overweight | $1,050 → $1,100 | $734.57 | +49.75% | 20 | Sep 13, 2024 | |
| OGN Organon & Co. | Downgrades: Underweight | $18 → $20 | $8.71 | +129.62% | 2 | Sep 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $48 → $41 | $27.01 | +51.80% | 11 | Feb 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $45 → $42 | $33.15 | +26.70% | 4 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $270 | $265.86 | +1.56% | 1 | Oct 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $36 → $34 | $22.28 | +52.60% | 10 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $120 → $125 | $75.97 | +64.54% | 7 | Feb 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $14 | $8.77 | +59.64% | 2 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $11 | $0.97 | +1,035.54% | 4 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $24 → $20 | $11.96 | +67.22% | 3 | Oct 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $4.59 | - | 4 | Jul 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $74 → $78 | $46.45 | +67.92% | 7 | Oct 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $700 → $950 | $3.42 | +27,677.78% | 4 | May 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.46 | - | 2 | May 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $45 → $50 | $25.12 | +99.04% | 3 | Nov 2, 2018 |
Biogen
May 5, 2025
Maintains: Neutral
Price Target: $185 → $175
Current: $118.17
Upside: +48.09%
Regeneron Pharmaceuticals
Mar 31, 2025
Maintains: Overweight
Price Target: $1,100 → $1,000
Current: $527.78
Upside: +89.47%
Gilead Sciences
Mar 27, 2025
Maintains: Overweight
Price Target: $120 → $130
Current: $96.91
Upside: +34.15%
Amneal Pharmaceuticals
Feb 24, 2025
Upgrades: Overweight
Price Target: $9 → $12
Current: $7.41
Upside: +61.94%
AbbVie
Nov 13, 2024
Maintains: Overweight
Price Target: $210 → $200
Current: $184.60
Upside: +8.34%
Teva Pharmaceutical Industries
Oct 21, 2024
Maintains: Neutral
Price Target: $16 → $18
Current: $16.93
Upside: +6.32%
IDEXX Laboratories
Oct 11, 2024
Maintains: Overweight
Price Target: $630 → $575
Current: $491.70
Upside: +16.94%
Zoetis
Oct 11, 2024
Maintains: Overweight
Price Target: $225 → $230
Current: $159.27
Upside: +44.41%
Eli Lilly and Company
Sep 13, 2024
Maintains: Overweight
Price Target: $1,050 → $1,100
Current: $734.57
Upside: +49.75%
Organon & Co.
Sep 6, 2024
Downgrades: Underweight
Price Target: $18 → $20
Current: $8.71
Upside: +129.62%
Feb 28, 2024
Maintains: Overweight
Price Target: $48 → $41
Current: $27.01
Upside: +51.80%
Feb 20, 2024
Maintains: Overweight
Price Target: $45 → $42
Current: $33.15
Upside: +26.70%
Oct 20, 2023
Reinstates: Neutral
Price Target: $270
Current: $265.86
Upside: +1.56%
Oct 16, 2023
Maintains: Neutral
Price Target: $36 → $34
Current: $22.28
Upside: +52.60%
Feb 23, 2023
Maintains: Overweight
Price Target: $120 → $125
Current: $75.97
Upside: +64.54%
Nov 15, 2022
Maintains: Neutral
Price Target: $13 → $14
Current: $8.77
Upside: +59.64%
Nov 14, 2022
Maintains: Neutral
Price Target: $13 → $11
Current: $0.97
Upside: +1,035.54%
Oct 17, 2022
Maintains: Neutral
Price Target: $24 → $20
Current: $11.96
Upside: +67.22%
Jul 29, 2022
Downgrades: Neutral
Price Target: n/a
Current: $4.59
Upside: -
Oct 16, 2020
Maintains: Overweight
Price Target: $74 → $78
Current: $46.45
Upside: +67.92%
May 27, 2020
Maintains: Overweight
Price Target: $700 → $950
Current: $3.42
Upside: +27,677.78%
May 19, 2020
Downgrades: Neutral
Price Target: n/a
Current: $1.46
Upside: -
Nov 2, 2018
Maintains: Neutral
Price Target: $45 → $50
Current: $25.12
Upside: +99.04%